HBV News and Research

RSS

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Microbial metabolites could help improve functional cure rates for hepatitis B

Chronic hepatitis B (CHB) remains a major global challenge. Current therapies suppress HBV but rarely achieve functional cure (sustained HBsAg loss).

30 Jul 2026

Europe risks missing target to eliminate viral hepatitis by 2030

While Europe has made steady progress in preventing hepatitis B and C, with the prevalence of hepatitis B now at near-zero levels among children below five years old, an uneven implementation of key measures means that the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat, according to new data from the European Centre for Disease Prevention and Control (ECDC) on World Hepatitis Day.

28 Jul 2026

Occult hepatitis B mutations drive liver cancer growth via Akt mTOR pathway

Occult hepatitis B virus (OBI) infection presents a significant global health challenge, notoriously flying under the radar of standard viral screening while relentlessly driving the pathogenesis of hepatocellular carcinoma (HCC).

22 Jul 2026

Study reveals mechanism underlying HBV-induced liver inflammation

Chronic hepatitis B virus (HBV) infection remains a major cause of global liver morbidity, leading to progressive necroinflammation that often culminates in cirrhosis and hepatocellular carcinoma.

17 Jul 2026

Strategic healthcare interventions bring Japan close to eliminating hepatitis

Hepatitis B (HBV) and hepatitis C (HCV) are viral infections that can lead to health conditions such as cirrhosis, cancer, and potentially death if unmanaged. HBV can be transmitted through sexual contact, blood exposure, and mother-to-child transmission, while HCV is primarily transmitted through blood-to-blood contact.

25 Jun 2026

Combination therapy improves response rates for chronic hepatitis B patients

The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This study aimed to investigate the efficacy and predictive factors of a pegylated interferon (Peg-IFN)-based treatment strategy in IT patients with chronic HBV infection.

22 May 2026

Optimized extended PCLS culture system extends tissue viability up to two weeks

Precision-cut liver slice (PCLS) technology has long been regarded as a promising ex vivo platform because it preserves the native multicellular architecture of liver tissue.

22 May 2026

Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection.

14 May 2026

WHO report shows measurable progress in reducing global hepatitis infections

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a new World Health Organization (WHO) report released today at the World Hepatitis Summit.

28 Apr 2026

Modeling the synergy of maternal screening and newborn HBV vaccination

Hepatitis B virus (HBV) infection acquired at birth or during early infancy can lead to lifelong health complications, including chronic liver disease. Despite longstanding recommendations for prenatal screening, an estimated 12% to 16% of pregnant individuals in the US are not screened for hepatitis B. This gap leaves a portion of newborns at risk for undetected exposure.

28 Apr 2026

Delaying hepatitis B birth vaccines increases infant infection risks

Delaying hepatitis B vaccination after birth increases infections among newborns and decreases their survival rates and quality of life, according to a new Cornell University study.

27 Apr 2026

Long-term study supports tenofovir alafenamide for chronic hepatitis B

Tenofovir alafenamide (TAF) has demonstrated comparable efficacy to tenofovir disoproxil fumarate (TDF), with improved renal and bone safety, in Chinese participants with chronic hepatitis B enrolled in two Phase 3 trials.

24 Apr 2026

AGA update calls for better surveillance of hepatocellular carcinoma

A new update from the American Gastroenterological Association (AGA) urges stronger prevention efforts and better early-detection tools for hepatocellular carcinoma (HCC), the leading cause of cancer-related death in patients with cirrhosis, and the third most common cause of cancer-related death worldwide.

17 Apr 2026

African health expert: genomic sequencing enables near real-time pathogen detection

Advanced genomic sequencing techniques, like mNGS, are essential for accurate pathogen detection, crucial for effective outbreak response and patient care.

From BGI Genomics 15 Apr 2026

Dynamic viral markers predict treatment response in hepatitis B

The rate of functional cure (HBsAg loss) remains unsatisfactory following pegylated interferon (PEG-IFN) treatment in chronic hepatitis B. To optimize PEG-IFN administration, this study aimed to evaluate virological markers to predict functional cure and/or hepatitis B e antigen (HBeAg) loss.

30 Jan 2026

Study develops highly accurate polygenic risk models tailored for Han Chinese populations

Researchers at Academia Sinica have developed the first population-specific polygenic risk score (PRS) models for people of Han Chinese ancestry, achieving unprecedented accuracy in predicting risks for common diseases such as diabetes, heart disease, autoimmune disorders.

20 Nov 2025

Study reveals trends and future projections of cancer mortality in China

Cancer remains the second leading cause of death in China, accounting for nearly one-quarter of all deaths nationwide. Rapid socioeconomic change, environmental exposure, and an aging population have intensified the burden of cancer across the country.

7 Nov 2025

Combination strategy may optimize interferon-based therapy for chronic hepatitis B

Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of hepatitis B virus (HBV) DNA, with significant myelosuppression leading to treatment discontinuation in some patients.

14 Oct 2025

Do tongue piercings harm your oral health? Evidence points to yes

Researchers reviewed 19 studies on tongue piercings and found they carry significant oral health risks, including fractures, gum recession, infections, and rare systemic complications. The evidence base is limited but highlights the need for clinician vigilance and patient awareness.

21 Sep 2025